The addition of pentoxifylline to conventional therapy improves outcome in patients with peripartum cardiomyopathy

European Journal of Heart Failure

Volumn 4, Issue 3, 2002, Pages 305-309

  Sliwa, Karen ^a   Skudicky, Daniel ^a   Candy, Geoffrey ^a   Bergemann, Anette ^a   Hopley, Mark ^a   Sareli, Pinhas ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Cardiomyopathy; Cytokines; Heart failure

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FUROSEMIDE; PENTOXIFYLLINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGE DISTRIBUTION; ARTICLE; CARDIOMYOPATHY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART RATE VARIABILITY; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HUMAN; PERIPARTUM CARDIOMYOPATHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; THIRD TRIMESTER PREGNANCY; TREATMENT OUTCOME;

ADULT; CARDIOMYOPATHIES; CARDIOTONIC AGENTS; ENZYME INHIBITORS; FEMALE; HUMANS; PENTOXIFYLLINE; PREGNANCY; PROSPECTIVE STUDIES; PUERPERAL DISORDERS; REGRESSION ANALYSIS; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0036623854     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-9842(02)00008-9     Document Type: Article

References (15)

1. Seftel H, Susser M. Maternity and myocardial failure in African woman. Br Heart J 1961;23:43-52.
2. Demakis JG, Rahimtoola SH, Sutton GC, Meadows R, Szanto PB, Tobin JR, Gunnar RM. Natural course of peripartum cardiomyopathy. Circulation 1971;44:1053-61.
3. Meadows WR. Idiopathic myocardial failure in the last trimester of pregnancy and the puerperium. Circulation 1957;15:903-14.
4. Sliwa K, Skudicky D, Bergemann A, Candy G, Sareli P. Peripartum cardiomyopathy: analysis of clinical outcome, left ventricular function, plasma levels of cytokines and Fas/APO-1. J Am Coll Cardiol 2000;35:701-5.
5. Sliwa K, Skudicky D, Candy G, Wisenbaugh T, Sareli P. Effects of pentoxifylline on left ventricular functions in patients with idiopathic dilated cardiomyopathy. Lancet 1998;351:1091-3.
6. Skudicky D, Bergemann A, Sliwa K, Candy G, Sareli P. Heart Failure Research Unit. Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin converting enzyme inhibitors and carvedilol. Circulation 2001;103:1083-8.
7. Sahn DJ, DeMaria A, Kisslo J, Weyman A. The committee on M-mode standardization of the American Society of Echocardiography. Recommendations regarding quantitation in M-mode echocardiography; results of a survey of echocardiographic measurements. Circulation 1978;58:1072-83.
8. Quinones MA, Pickering E, Alexander JK. Percentage of shortening of the echocardiographic left ventricular dimension: its use in determining ejection fraction and stroke volume. Chest 1978;7459-65.
9. Waage A, Sorensen M, Stordal B. Differential effects of pentoxifylline in tumor necrosis factor and interleukin 6 production. Lancet 1990;335:543.
10. Zabel P, Schonhartig MM, Wolter DT, Schade UF. Oxpentoxifylline in endotoxaemia. Lancet 1989;ii:1474-77.
11. Kremsner PG, Grundmann HJ, Neifer S, Sliwa K, Sahlmüller G, Hegenscheid B, Bienzle U. Pentoxifylline prevents murine cerebral malaria. J Infect Dis 1991;164:605-8.
12. Belloc F, Jaloustre C, Dumain P, Lacombe F, Lenoble M, Boisseau MR. Effect of pentoxifylline on apoptosis of cultured cells. J Cardiovasc Pharmacol 1995;25(suppl 2):S71-S74.
13. Schwarz A, Mahnke K, Luger TA, Schwarz T. Pentoxifylline reduces formation of sunburned cells. Exp Dermatol 1997;6:1-5.
14. Ontsuka T, Hamada M, Shigematsu Y, Hara Y, Suzuki M, Ikeda S, Sasaki O, Hiasa G, Ogimoto A, Hiwada K. Beta blockade modifies the abnormalities in levels of cytokines and cytokine moderators in patients with dilated cardiomyopathy. Circulation 1999;100:1-203.
15. Prabhu SD, Chandrasekar B, Murray DR, Freeman GL. Adrenergic blockade in developing heart failure. Effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. Circulation 2000;101:2103-9.